Department of Pathology, University Hospital for Tumors, Sestre Milosrdnice Clinical Hospital Centre, Zagreb, Croatia.
Anticancer Res. 2013 Jun;33(6):2509-15.
To determine the correlation of phosphorylated human epidermal growth factor receptor-2 (pHER2) with clinicopathological characteristics of breast cancer (BC) and patients' response to trastuzumab-based therapy.
pHER2 was determinated immuno-histochemically in 88 cases of HER2-positive and 50 cases of HER2-negative BC. All patients with HER2-positive BC received trastuzumab-based therapy and 16 of them (18.2%) had disease progression during therapy treatment (i.e. trastuzumab-resistant).
pHER2 was predominantly expressed in HER2-positive BC, with 55 cases (62.5%) of tumours expressing pHER2. Six cases of HER2-negative cancer (12.5%) displayed positive expression of pHER2. Expression of pHER2 correlated with younger age of patients and negative oestrogen receptor status. Acquisition of resistance to trastuzumab correlated with negativity for pHER2 (p=0.028).
Positive expression of pHER2 may yield additional information regarding the poor prognosis of BC and could be used for pre-selection of patients with HER2-overexpressing BC displaying resistance to trastuzumab treatment.
确定磷酸化人表皮生长因子受体-2（pHER2）与乳腺癌（BC）的临床病理特征及患者对曲妥珠单抗为基础的治疗反应之间的相关性。
对 88 例 HER2 阳性和 50 例 HER2 阴性 BC 患者进行免疫组化测定 pHER2。所有 HER2 阳性 BC 患者均接受曲妥珠单抗为基础的治疗，其中 16 例（18.2%）在治疗过程中发生疾病进展（即曲妥珠单抗耐药）。
pHER2 在 HER2 阳性 BC 中表达为主，其中 55 例（62.5%）肿瘤表达 pHER2。6 例 HER2 阴性癌症（12.5%）显示 pHER2 阳性表达。pHER2 的表达与患者年龄较小和雌激素受体阴性状态相关。对曲妥珠单抗产生耐药性与 pHER2 阴性相关（p=0.028）。
pHER2 的阳性表达可能提供有关 BC 不良预后的额外信息，并可用于选择对曲妥珠单抗治疗耐药的 HER2 过表达 BC 患者。
